Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela

Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; VenezuelaFil: Diaz Bello, Zoraida. Universidad Central de Venezuela; VenezuelaFil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; VenezuelaFil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; VenezuelaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; Venezuel

Characterization and follow-up of Trypanosoma cruzi natural populations refractory to etiological chemotherapy in oral chagas disease patients

We aimed to characterize the genetic constitution of natural T. cruzi populations involved in an Oral Chagas Disease (OCD) outbreak at a rural school of the community of Chichiriviche de la Costa, Venezuela, which affected patients did not respond to the etiological treatment. Peripheral blood samples and/or hemocultures were obtained from twenty-nine OCD patients at time of diagnosis or along nine years of Post-treatment (Tx) follow-up. The IgG serology, T. cruzi discrete typing units (DTU), satellite DNA-qPCR parasitic loads, and minicircle signatures were determined at Pre-Tx and after Tx. The serological titles and parasitic loads changed after treatment, with a significant decrease of IgG titers (Spearman’s r value= -0.961) and median parasite loads from 2.869 [IQR = 2.113 to 3.720] to 0.105 [IQR = -1.147 to 1.761] log10 par eq. /mL at Pre-Tx and Post-Tx, respectively, suggesting infection evolution from acute to chronic phase, without seroconversion or parasitological eradication, which was indicative of treatment failure. All patients were infected with T. cruzi DTU I populations. At Pre-Tx their median Jaccard genetic distances were 0.775 [IQR = 0.708 to 0.882], decreasing in genetic variability towards the end of follow-up (Mann-Whitney U test p= 0.0031). Interestingly, no Post-Tx minicircle signature was identical to its Pre-Tx counterpart population in a same patient, revealing selection of parasite subpopulations between the primary infection and Post-Tx. The parasitic populations isolated from hemocultures showed a lower number of bands in the minicircle signatures with respect to the signatures obtained directly from the patients’ blood samples, demonstrating a process of parasitic selection and reduction of the population variability that initially infected the patients. Decrease of parasitic loads after treatment as well as Pre- and Post-Tx intra-TcI diversity might be a consequence of both, natural evolution of the acute infection to the chronic phase and persistence of refractory populations due to Tx selection.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Díaz Bello, Zoraida. Universidad Central de Venezuela; VenezuelaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; VenezuelaFil: Noya González, Oscar O.. Universidad Central de Venezuela; VenezuelaFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentin

Seroprevalence of Trypanosoma cruzi infection in dogs and cats in the north central bioregion of Venezuela

La enfermedad de Chagas (ECh) es una parasitosis del grupo de enfermedades desatendidas de la OMS. Endémica del continente americano, la transmisión se realiza en ciclos selvático, peridomiciliario y domiciliario. Epidemiológicamente, los caninos y felinos constituyen una fuente importante de infección y son centinelas de la transmisión. El perro es un hospedador común e importante del parásito ya que la presencia y número de caninos infectados en la vivienda del hombre constituyen factores de riesgo de transmisión doméstica de Trypanosoma cruzi. El presente estudio reporta la seroprevalencia de la infección por T. cruzi en la bioregión centro norte de Venezuela (Distrito Capital, Chichiriviche de la Costa del Estado La Guaira y parte del Estado Miranda), en 301 perros y 49 gatos empleando el ensayo inmunoenzimatico (ELISA). La prevalencia global en perros fue del 30,2 % en las tres zonas estudiadas mientras que en gatos fue de 40,8 %. Con relación al sexo de los animales, se encontró una prevalencia general de perros hembras del 27,6 % y para los perros machos del 33,1%. Los gatos machos presentaron una prevalencia mayor que las hembras en todas las localidades. Tanto en perros como en gatos la distribución de seropositividad fue mayor en animales intradomicilio. Se evidenció diferencia en los valores de ELISAIgG para las poblaciones de perros muestreados en la localidad de Petare comparado con perros presentes en la localidad de Aricagua (perros de caza), (p=0,006). En líneas generales, esta última localidad presentó una media de densidad óptica para la prueba de ELISA-IgG de 0,959 [0,369 - 1,975]. La presencia de perros y gatos infectados es un factor de riesgo actual de infección por T. cruzi para el hombre tanto en el medio rural como en el urbano.Chagas disease (ChD) is a parasitic infection in the WHO Neglected Diseases group. Endemic to the american continent, transmission takes place in sylvatic, peridomiciliary and domestic cycles. Epidemiologically, canines and felines constitute an important source of infection and are sentinels of transmission. The dog is a common and important host of the parasite, since the presence and number of infected canines in the man's house are risk factors for domestic transmission of Trypanosoma cruzi. This study reports the seroprevalence of T. cruzi infection in the north-central bioregion of Venezuela (Capital District, Chichiriviche de la Costa, La Guaira State, and part of Miranda State), in 301 dogs and 49 cats using the immunoenzymatic assay (ELISA). The overall prevalence in dogs was 30.2 % in the three studied areas, while in cats it was 40.8 %. Regarding the sex of the animals, a general prevalence of 27.6 % for female dogs and 33.1% for male dogs was found. Male cats presented a higher prevalence than females in all localities. In both, dogs and cats, the distribution of seropositivity was greater in indoor animals. There was of a difference in ELISA-IgG values for the populations of dogs sampled in the town of Petare compared to dogs present in the town of Aricagua (hunting dogs), (p=0.006). In general, this last locality presented a mean optical density for the ELISA-IgG test of 0.959 [0.369 - 1.975]. The presence of infected dogs and cats is a current risk factor for T. cruzi infection for man in both of them in the rural and in the urban environment.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad Central de Venezuela; VenezuelaFil: Bello, Zoraida Diaz. Universidad Central de Venezuela; VenezuelaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; VenezuelaFil: Beitia, Yubiri. Unidad Móvil Veterinaria; Venezuel

Towards the establishment of a single standard curve for quantification of Trypanosoma cruzi natural populations using a synthetic satellite unit DNA sequence

Accurate diagnostics tools and surrogate markers of parasitological response to treatment are priority needs for management of Chagas disease. Quantitative real-time PCR (qPCR) is used for treatment monitoring, but variability in copy dosage and sequences of molecular target genes among different Trypanosoma cruzi strains limit the precision of quantitative measures. To improve qPCR quantification accuracy, we designed and evaluated a synthetic DNA molecule containing a Satellite DNA (satDNA) repeat unit as standard for quantification of T. cruzi loads in clinical samples, independently of the parasite strain. Probit regression analysis established for Dm28c (Tc I) and CL-Brener (Tc VI) stocks similar LOD95 values (0.903 (0.745-1.497) and 0.667 (CI 0.113-3.927) copy numbers/μL, respectively), when synthetic DNA was the standard for quantification, thus allowing direct comparison of loads in samples infected with different DTUs. This standard curve was evaluated in 205 samples from 38 acute oral and 19 chronic CD patients from different geographical areas infected with different genotypes, including samples obtained during treatment follow-up, and high agreement with parasitic load trends using standard curves based on DNA extracted from spiked blood with counted parasites was obtained. This qPCR-based quantification strategy will be a valuable tool in phase III clinical trials, to follow-up patients under treatment or at risk of reactivation and in experimental models using different parasite strains.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Silva Gomess, Natalia Lins. Fundación Oswaldo Cruz; BrasilFil: Apodaca, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; VenezuelaFil: Díaz Bello, Zoraida. Universidad Central de Venezuela; VenezuelaFil: Quintino Souza, Leticia Rocha. Fundación Oswaldo Cruz; BrasilFil: Tavares Costa, Alexandre Dias. Fundación Oswaldo Cruz; BrasilFil: Britto, Constança. Fundación Oswaldo Cruz; BrasilFil: Moreira, Otacilio Cruz. Fundación Oswaldo Cruz; BrasilFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentin

Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.

Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change